Related Experiment Video
Updated: Sep 15, 2025
Subretinal Injection of Gene Therapy Vectors and Stem Cells in the Perinatal Mouse Eye
Published on: November 25, 2012
Preventing vision loss in a mouse model of Leber Congenital Amaurosis by engineered tRNA
Enes Akyuz1,2, Pawan K Shahi1,2, Lionel Gissot3
1University of Wisconsin-Madison, Department of Pediatrics, Wisconsin, USA.
Abstract:
Premature termination codons (PTCs) are associated with rare genetic disorders. Inducing targeted read-through of these 'nonsense mutations' presents a potential therapeutic strategy for modifying disease outcomes. We previously reported that one such PTC, W53X, in the KCNJ13 gene causes blindness and Leber congenital amaurosis type-16 (LCA-16) due to loss of function of the inwardly rectifying potassium channel 7.1 (Kir7.1). Here, we present the proof of concept of a therapeutic approach based on anticodon-engineered transfer RNA (ACE-tRNA). The ACE-tRNA encodes the amino acid tryptophan (Trp) and suppresses the W53X PTC, restoring full-length protein expression. We used helper-dependent adenovirus (HDAd) to deliver the ACE-tRNATrp.UAG (tRNATrp.UAG) and rescue Kir7.1 function and physiology in patient-specific human induced pluripotent stem cell-derived retinal pigment epithelium (hiPSC-RPE) cells. Furthermore, in a W53X mouse model of LCA16, HDAd delivery of tRNATrp.UAG resulted in durable restoration of vision as measured by retinography. This study provides the first example of the therapeutic application of ACE-tRNA for treating an inherited form of blindness.
Insights
Anticodon-engineered transfer RNA (ACE-tRNA) therapy successfully restored vision in a mouse model of Leber congenital amaurosis type-16. This approach targets nonsense mutations, offering a potential treatment for inherited blindness.
Area of Science:
- Genetics
- Ophthalmology
- Molecular Biology
Background:
- Premature termination codons (PTCs) cause rare genetic disorders by introducing nonsense mutations.
- Leber congenital amaurosis type-16 (LCA-16) results from a PTC (W53X) in the KCNJ13 gene, leading to Kir7.1 channel dysfunction and blindness.
Purpose of the Study:
- To demonstrate the therapeutic potential of anticodon-engineered transfer RNA (ACE-tRNA) for treating inherited blindness caused by nonsense mutations.
- To restore the function of the Kir7.1 channel by suppressing the W53X PTC.
Main Methods:
- Developed ACE-tRNA (tRNATrp.UAG) to suppress the W53X PTC and restore tryptophan insertion.
- Utilized helper-dependent adenovirus (HDAd) for gene delivery of tRNATrp.UAG.
- Tested the therapy in patient-derived human induced pluripotent stem cell-derived retinal pigment epithelium (hiPSC-RPE) and a W53X mouse model of LCA16.
Main Results:
- ACE-tRNATrp.UAG successfully suppressed the W53X PTC in hiPSC-RPE cells, restoring Kir7.1 function.
- HDAd-mediated delivery of tRNATrp.UAG in the W53X mouse model led to durable vision restoration.
- Retinography confirmed significant visual recovery in treated mice.
Conclusions:
- ACE-tRNA represents a novel therapeutic strategy for genetic disorders caused by nonsense mutations.
- This study provides the first proof-of-concept for ACE-tRNA therapy in treating inherited blindness.
- The findings open new avenues for developing treatments for various rare genetic diseases.
